Overview

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Status:
RECRUITING

Trial end date:
2032-02-06

Target enrollment:

Participant gender:

Summary

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Acetaminophen
Adjuvants, Pharmaceutic
Carboplatin
Cisplatin
Dexamethasone
Gemcitabine
Histamine Antagonists
Histamine H2 Antagonists
Neoadjuvant Therapy
Paclitaxel
pembrolizumab
Pemetrexed